BioSpace News Archive

Walgreens Boots Alliance announced the publication of its 2019 Corporate Social Responsibility Report, which details the company’s global sustainability initiatives, including efforts to improve access to quality healthcare, deliver support programs for people living with cancer and reduce its carbon footprint.

Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of an underwritten registered public offering of 2,125,000 of its common shares at a price to the public of $4.00 per share

ALRT will demonstrate proof of its remote diabetes patient management concept in partnership with Singapore General Hospital

Predictive Technology Group announced that its wholly owned subsidiary, Predictive Laboratories, received interim beta test results from its ARTguide™ test evaluating over 1,000 patients for risk of endometriosis at beta clinical sites.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), today announced that PB2452 has been granted PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA) for reversal of the antiplatelet effects of ticagrelor in patients with uncontrolled major or life-threatening bleeding or requiring urgent surgery or an invasive procedure.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced its plan to initiate a Phase I clinical trial for Berubicin in pediatric brain cancer in Poland in collaboration with WPD Pharmaceuticals, Inc. (CSE: WBIO) (“WPD”), a Polish corporation founded by Dr. Waldemar Priebe, the founder of the Company.

Dermata Therapeutics, LLC, a privately held biotechnology company, announced today that it has completed enrollment of patients in its Phase 2b clinical trial evaluating the safety, tolerability and efficacy of DMT310 in moderate to severe acne patients.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) today announced that Robb Knie, Chief Executive Officer, will be presenting at the Noble Capital Markets’ Sixteenth Annual Investor Conference on February 18, 2020 at the Hard Rock Hotel & Casino, Hollywood, Florida.

Seven dramatic weeks have passed since the Chinese health authorities informed the World Health Organization about the Coronavirus 2019-CoV. Coronavirus is closely related to the SARS virus.